Loading
companiesCompany
Lupeng Pharmaceuticals
Lupeng Pharmaceuticals is a China-based biotechnology company that leads 4 cancer trials in OnCo, testing the Bcl-2 inhibitor lacutoclax (LP-108) and the BTK inhibitor rocbrutinib (LP-168) in chronic lymphocytic leukaemia, mantle cell lymphoma, diffuse large B-cell lymphoma and follicular lymphoma.
Also called: Guangzhou Lupeng Pharmaceutical鲁鹏医药
Overview
Lupeng Pharmaceuticals develops next-generation small-molecule targeted drugs for malignant tumours and autoimmune diseases, focused on haematological cancers and the BTK, Bcl-2 and Bcl-xL pathways. Its site states that rocbrutinib (LP-168) is approved by China's NMPA and that lacutoclax (LP-108) has entered pivotal registration studies. On ClinicalTrials.gov it is the lead sponsor of 4 trials recorded in OnCo: NCT07609823 (phase 2, A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL), NCT07609862 (phase 1/2, A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies), NCT05716087 (phase 2, A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma) and NCT07189065 (phase 2, A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Guangzhou, CN
Scorecard
All companies#50of 1244 companies, score 72
- approved products +18
- phase 3 +3
- targets +6
- modalities +8
- regions +7
- registry trials +30
3 approved, 1 in phase 3, 0 earlier, 3 targets, 3,333 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
Phase 3small molecule
Rocbrutinib is an experimental small-molecule drug from Guangzhou Lupeng Pharmaceutical in phase 3 trials for mantle cell lymphoma, chronic lymphocytic leukaemia and diffuse large B-cell lymphoma, with its target not yet stated publicly.
ApprovedAlkylating agent (nitrogen mustard-purine hybrid)
Bendamustine · Treanda / Bendeka / Belrapzo
An East German chemotherapy rediscovered in the 2000s that became the backbone partner for rituximab in follicular, mantle cell and Waldenström lymphomas.
ApprovedMonoclonal antibody (anti-CD20, chimeric)
Rituximab · Rituxan / MabThera (and biosimilars)
Rituximab was the first antibody ever approved for cancer (1997). It made chemoimmunotherapy the CLL standard for a decade, and biosimilars keep it cheap and everywhere.
ApprovedImmunomodulatory drug (cereblon E3 ligase modulator)
Lenalidomide · Revlimid
Lenalidomide is a thalidomide descendant that glues the proteins IKZF1 and IKZF3 to cereblon so the cell destroys them, killing plasma cells and rousing T cells. It is the backbone of myeloma treatment and maintenance, also used in mantle cell and follicular lymphoma, and generic since 2022.
Similar pages
- TrialStudy to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Shares Bendamustine, Mantle cell lymphoma, Follicular lymphoma, Diffuse large B-cell lymphoma.
- TrialA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Shares Bendamustine, Lenalidomide, Rituximab, Mantle cell lymphoma.
- CancerSplenic B-cell lymphoma/leukaemia with prominent nucleoli (formerly B-cell prolymphocytic leukaemia and hairy cell leukaemia variant)
Shares Bendamustine, Rituximab, Mantle cell lymphoma, Chronic lymphocytic leukaemia.
- TrialROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Shares Rocbrutinib, Chronic lymphocytic leukaemia.
- CompanySymBio Pharmaceuticals
Shares Bendamustine, Mantle cell lymphoma, Follicular lymphoma.
- TrialSafety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Shares Lenalidomide, Rituximab, Follicular lymphoma, Diffuse large B-cell lymphoma.
- TrialA Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Shares Lenalidomide, Rituximab, Follicular lymphoma.
- TrialRELEVANCE
Shares Bendamustine, Lenalidomide, Rituximab, Follicular lymphoma.
cancers
drugs
ApprovedAlkylating agent (nitrogen mustard-purine hybrid)
Bendamustine · Treanda / Bendeka / Belrapzo
ApprovedImmunomodulatory drug (cereblon E3 ligase modulator)
Lenalidomide · Revlimid
ApprovedMonoclonal antibody (anti-CD20, chimeric)
Rituximab · Rituxan / MabThera (and biosimilars)
Phase 3small molecule
trials
A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLLA Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell MalignanciesA Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell LymphomaA Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaA Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma